Wang Ling, Zhang Xia, Xue Yu-wen, Li Yu, Shi Qing, Liu Chun-hong
Department of Respiratory Disease, The Qilu Hospital of Shandong University, Jinan 250012, China.
Zhonghua Nei Ke Za Zhi. 2003 Jan;42(1):24-6.
To observe the changes of serum interleukin (IL)-12, IL-13 and lung function in asthmatic patients and to evaluate the influence of glucocorticoid on them.
The serum samples were obtained from (1) 25 asthmatic patients with acute asthma attack before and after one week course of oral prednisone, (2) 20 asthmatic patients in remission stage, and (3) 15 healthy volunteers. Serum IL-12 and IL-13 were determined with sandwich ELISA. Lung ventilatory function forced expiratory volume in one second (FEV(1)) and respiratory impedance airway resistance (R(5)) were measured in all patients.
(1) Serum level of IL-12 in asthma attack group was significantly lower than that in asthma remission group (P < 0.05); both were significantly lower than that in normal control group (P < 0.01); in asthma attack group IL-12 level after prednisone treatment was significantly higher than that before treatment (P < 0.01). (2) Serum level of IL-13 in asthma attack group was significantly higher than that in asthma remission group (P < 0.01); both were significantly higher than that in normal control group (P < 0.01); in asthma attack group IL-13 level after prednisone treatment was significantly lower than that before treatment (P < 0.01). Correlation analysis showed that the serum level of IL-12 was positively correlated to FEV(1) and negatively correlated to R(5) and to serum level of IL-13 (r(1) = 0.458, r(2) = -0.516, and r(3) = -0.549, respectively; P < 0.05 and P < 0.01); the serum level of IL-13 was negatively correlated to FEV(1) and positively correlated to R(5) (r(1) = -0.493, and r(2) = 0.528, respectively; P < 0.05).
The secretion of IL-12 and IL-13 was impaired in asthma with a significant increase in serum level of IL-13 and decrease in serum level of IL-12. Glucocorticoid could downregulate the serum level of IL-13 and upregulate the serum level of IL-12, redress the imbalance of IL-12/IL-13, and improve lung function in asthmatic patients.
观察哮喘患者血清白细胞介素(IL)-12、IL-13及肺功能的变化,并评估糖皮质激素对其的影响。
采集血清样本,来自(1)25例急性哮喘发作的哮喘患者口服泼尼松一周疗程前后;(2)20例哮喘缓解期患者;(3)15名健康志愿者。采用夹心ELISA法测定血清IL-12和IL-13。测量所有患者的肺通气功能一秒用力呼气容积(FEV(1))和呼吸阻抗气道阻力(R(5))。
(1)哮喘发作组血清IL-12水平显著低于哮喘缓解组(P<0.05);两者均显著低于正常对照组(P<0.01);哮喘发作组泼尼松治疗后IL-12水平显著高于治疗前(P<0.01)。(2)哮喘发作组血清IL-13水平显著高于哮喘缓解组(P<0.01);两者均显著高于正常对照组(P<0.01);哮喘发作组泼尼松治疗后IL-13水平显著低于治疗前(P<0.01)。相关性分析显示,血清IL-12水平与FEV(1)呈正相关,与R(5)及血清IL-13水平呈负相关(r(1)=0.458,r(2)=-0.516,r(3)=-0.549,P<0.05和P<0.01);血清IL-13水平与FEV(1)呈负相关,与R(5)呈正相关(r(1)=-